FemTech Appoints Russell M. Medford, MD, Ph.D. as US-Based Board Chairperson
PHILADELPHIA, August 23, 2022 — N2Growth Inc., a global leadership consulting and executive search firm placed Russell M. Medford, MD, Ph.D., as Board Chairperson of Atlantic Therapeutics. The appointment of Dr. Medford to the Board is a significant step toward fulfilling the potential of the INNOVO® brand in the large and under-served US stress urinary incontinence (SUI) market. The board search was led by Jessica Toth, Senior Director at N2Growth.
Susan Trent, Atlantic Therapeutics CEO, commented, “I am delighted to welcome Dr. Medford to the Atlantic Therapeutics Board. His experience in both clinical and commercial environments, as well as his obvious passion for delivering effective and innovative healthcare solutions in areas of unmet need, will be a major catalyst to maximize the potential for INNOVO®.”
Based in Galway, Ireland, and Boston, MA, Atlantic Therapeutics develops consumer medical devices, related software, apps and connected health technologies to treat all types of incontinence. The company’s mission is to improve the quality of life of millions of people each year by enabling them to restore and strengthen their pelvic health, thus regaining the confidence and control to lead active lives. Atlantic Therapeutics has attracted international VC investment and enterprise grant funding and is experiencing high growth, establishing INNOVO® as the leading Femtech solution to treat SUI.
Dr. Medford is a senior healthcare and life sciences executive with extensive private and public company experience. Currently, he serves as Chairman and CEO of Covanos Inc., a medical technology company focused on advanced cardiovascular diagnostics.
He has also led companies and organizations engaged in comprehensive therapeutic drug research and development and has executed multiple strategic partnerships with major pharmaceutical companies.
He has extensive experience in private and public financial markets, including initial public offerings raising over $500 million for corporate, clinical development, and research programs and returning over $2.5 billion in shareholder value. He currently serves as a Board member of ThermoGenesis Holdings (Nasdaq: THMO), engaged in developing and commercializing automated cell processing technologies for cell and gene therapy. He has served on multiple public and private company Boards.
Dr. Medford is a board-certified physician, an inaugural Fellow of the Council on Basic Cardiovascular Sciences of the American Heart Association, and has held faculty positions at Harvard Medical School and the Emory University School of Medicine.
He currently serves as Chairman of the Center for Global Health Innovation, past Chairman and current member of the External Advisory Board for the Petit Institute of Bioscience and Bioengineering of the Georgia Institute of Technology, and the Executive Committee of the Board of Directors for the Global Center for Medical Innovation.
On joining the Board of Atlantic Therapeutics, Dr. Medford commented: “From the first conversations with CEO, Susan Trent, and other Board members, I could clearly see the huge potential of INNOVO® to positively change the outcome for women living with SUI. This very prevalent yet under-served condition impacts the lives of millions of women. It requires a treatment that is safe, clinically proven, and easily accessible.”
Jessica Toth, Senior Director at N2Growth, added, “We were thrilled to partner with the Board and leadership team at Atlantic Therapeutics for this critical hire. An emerging market and an innovative product that supports women’s health made this a particularly satisfying placement for the team. We are pleased to have found such a tremendous leader in Dr. Medford.”
